Paxlovid Misses in Standard-Risk COVID-19

Paxlovid Misses in Standard-Risk COVID-19 Trend toward advantage in secondary endpoint of hospitalization or death, but not significant Kristina Fiore medpagetoday

Updated findings from a nirmatrelvir/ritonavir (Paxlovid) trial in standard-risk COVID-19 suggest the antiviral's benefits are less clear for those not at high risk of severe outcomes.

As was previously reported, Pfizer's so-called EPIC-SR (standard risk) trial failed to meet its primary endpoint: a relative risk reduction in self-reported, sustained alleviation of all symptoms for 4 consecutive days....